抗FOLR1抗体药物偶联物治疗晚期卵巢癌的患者结局
本回顾性研究纳入170例复发/持续性FOLR1高表达高级别浆液性卵巢癌患者,接受标准米维妥昔单抗索拉坦辛(MIRV)单药治疗。中位无进展生存期(PFS)为3.5个月(95%CI 3.0-4.1),22.4%患者PFS≥6个月;既往紫杉烷进展者PFS和总生存期(OS)更差。FOLR1表达在MIRV后样本中降低,神经病变和眼毒性常见。
要点
- MIRV单药治疗复发/持续性FOLR1高表达HGSOC的中位PFS为3.5个月(95%CI 3.0-4.1)。
- 22.4%患者PFS≥6个月,且更少在既往紫杉烷治疗中或治疗后1个月内进展(P=0.008)。
- 既往紫杉烷进展者PFS更差(HR 1.69;95%CI 1.19-2.40;校正P=0.003),OS更差(HR 2.34;95%CI 1.45-3.77;校正P=0.0005)。
核心结论
- MIRV为部分HGSOC患者带来有意义的PFS获益。
- 耐药可能与FOLR1靶点表达降低或载荷耐药相关。
- 对于MIRV进展但肿瘤仍保留高FOLR1表达的患者,应评估使用不同载荷的FOLR1靶向ADC。
研究设计与样本
- 回顾性研究,纳入170例复发/持续性FOLR1高表达(≥75%肿瘤细胞≥2+膜染色强度)HGSOC患者,接受标准治疗MIRV单药。
- 采用Kaplan-Meier法和多变量Cox比例风险模型评估PFS和OS,不良事件按CTCAE v5.0分类。
主要发现
- 总体中位PFS为3.5个月(95%CI 3.0-4.1)。
- 22.4%患者PFS≥6个月,且更少在既往紫杉烷治疗中或治疗后1个月内进展(P=0.008)。
- 既往紫杉烷进展者PFS更差(HR 1.69;95%CI 1.19-2.40;校正P=0.003),OS更差(HR 2.34;95%CI 1.45-3.77;校正P=0.0005)。
- MIRV后样本(n=12)中FOLR1表达较低(P=0.005)。
- 新发或加重神经病变见于37.6%患者;34.1%患者发生眼毒性,中位发生时间为42.5天;5.3%患者因毒性停药。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mirvetuximab soravtansine-gynx (MIRV) is a FOLR1-binding antibody-drug conjugate (ADC) with a microtubule inhibitor payload. We investigated MIRV's efficacy, toxicity profile, and determinants of resistance in a cohort of patients with recurrent/persistent high FOLR1-expressing high-grade serous ovarian cancer (HGSOC). METHODS: This retrospective study included 170 patients with recurrent/persistent FOLR1-high (≥75 % of tumor cells with ≥2+ membranous staining intensity) HGSOC who received standard-of-care MIRV monotherapy. We evaluated progression-free survival (PFS) and overall survival (OS) using the Kaplan-Meier method and multivariable Cox proportional hazards models. We classified adverse events using CTCAE v5.0. RESULTS: Overall, median PFS was 3.5 months (95 % CI, 3.0-4.1). However, 22.4 % had PFS ≥6 months and were less likely to have progressed on or within one month of prior taxane-based therapy (P = 0.008). Patients with previous progression on a taxane had worse PFS (HR, 1.69; 95 % CI, 1.19-2.40; adjusted P = 0.003) and OS (HR, 2.34; 95 % CI, 1.45-3.77; adjusted P = 0.0005). FOLR1 expression was lower in post-MIRV samples (n = 12; P = 0.005). New or worsening neuropathy was observed in 37.6 % of patients. Among the 34.1 % who experienced ocular toxicity, median onset was 42.5 days. Treatment was discontinued in 5.3 % of patients due to toxicity. DISCUSSION: MIRV confers meaningful PFS benefit for a subset of individuals with HGSOC. Resistance may be associated with decreased FOLR1 target expression or payload resistance. FOLR1-targeted ADCs with a different payload should be evaluated for patients who progress on MIRV but retain high tumor FOLR1 expression.
引用
- Johannet P, Flint M, Chui MH, et al. Patient outcomes in advanced ovarian cancer treated with an anti-FOLR1 antibody-drug conjugate. Gynecol Oncol. 2025. PMID: 40121972. doi:10.1016/j.ygyno.2025.03.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。